Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth?

Journal of Infectious Diseases

Volumn 193, Issue 9, 2006, Pages 1195-1201

  Cotter, Amanda M ^a   Garcia, Adolfo Gonzalez ^a   Duthely, M Lunthita ^a   Luke, Barbara ^b   O'Sullivan, Mary J ^a  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; ZIDOVUDINE;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GESTATIONAL AGE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PREGNANCY; PREGNANCY COMPLICATION; PREMATURE LABOR; PRIORITY JOURNAL; STILLBIRTH;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; DISEASE TRANSMISSION, VERTICAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INFANT, LOW BIRTH WEIGHT; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY OUTCOME; PREMATURE BIRTH; RISK; STILLBIRTH;

EID: 33646038009     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/503045     Document Type: Article

References (15)

1. Public Health Service Task Force. Recommendations for the use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States 2005. Available at: http://AIDSinfo.nih.gov. Accessed 17 August 2005.
2. Minkoff H, Augenbraun M. Antiretroviral therapy for pregnant women. Am J Obstet Gynecol 1997; 176:478-89.
3. Lorenzi P, Spicher VM, Laubereau B, et al. Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study. AIDS 1998; 12:F241-7.
4. Newell ML, Dunn DT, Peckham CS, Semprini AE, Pardi G. Vertical transmission of HIV-1: maternal immune status and obstetric factors. The European Collaborative Study. AIDS 1996; 10:1675-81.
5. The European Collaborative Study and the Swiss Mother + Child HIV Cohort Study. Combination antiretroviral therapy and duration of pregnancy. AIDS 2000; 14:2913-20.
6. Tuomala RE, Shapiro DE, Mofenson LM, et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med 2002; 346:1863-70.
7. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1993; 41:1-19.
8. Rosenak D, Diamant YZ, Yaffe H, Hornstein E. Cocaine: maternal use during pregnancy and its effect on the mother, the foetus and the infant. Obstet Gynecol Surv 1990; 45:348-59.
9. McDonald AD, Armstrong BG, Sloan M. Cigarette, alcohol and coffee consumption and prematurity. Am J Public Health 1992; 82:87-90.
10. Morriss AB, Cu-Uvin S, Harwell JI, et al. Multicenter review of protease inhibitors in 89 pregnancies. J Acquir Immune Defic Syndr 2000; 25:306-11.
11. Lambert JS, Watts DH, Mofenson L, et al. Risk factors for preterm birth, low birth weight and intrauterine growth retardation in infants born to HIV-infected pregnant women receiving zidovudine. AIDS 2000; 14:1389-99.
12. Cotter A, Duthely ML, O'Sullivan MJ, Romaguera R. Antiretroviral therapy and preterm delivery; another clue in the puzzle? Am J Obstet Gynecol 2004; 191:S59.
13. European Collaborative Study. Maternal viral load and vertical transmission of HIV-1: an important factor but not the only one. AIDS 1999; 13:1377-85.
14. Simonds RJ, Steketee R, Nesheim S, et al. Impact of zidovudine use on risk and risk factors for perinatal transmission of HIV. AIDS 1998; 12:301-8.
15. Mandelbrot L, Mayaux MJ, Bongain A, et al. Obstetric factors and mother-to-child transmission of human immunodeficiency virus type 1: the French perinatal cohorts. Am J Obstet Gynecol 1996; 175:661-7.